Literature DB >> 19672245

Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors.

Ute Modlich1, Susana Navarro, Daniela Zychlinski, Tobias Maetzig, Sabine Knoess, Martijn H Brugman, Axel Schambach, Sabine Charrier, Anne Galy, Adrian J Thrasher, Juan Bueren, Christopher Baum.   

Abstract

Gene transfer vectors may cause clonal imbalance and even malignant cell transformation by insertional upregulation of proto-oncogenes. Lentiviral vectors (LV) with their preferred integration in transcribed genes are considered less genotoxic than gammaretroviral vectors (GV) with their preference for integration next to transcriptional start sites and regulatory gene regions. Using a sensitive cell culture assay and a series of self-inactivating (SIN) vectors, we found that the lentiviral insertion pattern was approximately threefold less likely than the gammaretroviral to trigger transformation of primary hematopoietic cells. However, lentivirally induced mutants also showed robust replating, in line with the selection for common insertion sites (CIS) in the first intron of the Evi1 proto-oncogene. This potent proto-oncogene thus represents a CIS for both GV and LV, despite major differences in their integration mechanisms. Altering the vectors' enhancer-promoter elements had a greater effect on safety than the retroviral insertion pattern. Clinical grade LV expressing the Wiskott-Aldrich syndrome (WAS) protein under control of its own promoter had no transforming potential. Mechanistic studies support the conclusion that enhancer-mediated gene activation is the major cause for insertional transformation of hematopoietic cells, opening rational strategies for risk prevention.

Entities:  

Mesh:

Year:  2009        PMID: 19672245      PMCID: PMC2835038          DOI: 10.1038/mt.2009.179

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  37 in total

1.  Overcoming promoter competition in packaging cells improves production of self-inactivating retroviral vectors.

Authors:  A Schambach; D Mueller; M Galla; M M A Verstegen; G Wagemaker; R Loew; C Baum; J Bohne
Journal:  Gene Ther       Date:  2006-06-08       Impact factor: 5.250

2.  Retroviral vector insertion sites associated with dominant hematopoietic clones mark "stemness" pathways.

Authors:  Olga S Kustikova; Hartmut Geiger; Zhixiong Li; Martijn H Brugman; Stuart M Chambers; Chad A Shaw; Karin Pike-Overzet; Dick de Ridder; Frank J T Staal; Gottfried von Keudell; Kerstin Cornils; Kalpana Jekumar Nattamai; Ute Modlich; Gerard Wagemaker; Margaret A Goodell; Boris Fehse; Christopher Baum
Journal:  Blood       Date:  2006-11-21       Impact factor: 22.113

3.  Improving transcriptional termination of self-inactivating gamma-retroviral and lentiviral vectors.

Authors:  Axel Schambach; Melanie Galla; Tobias Maetzig; Rainer Loew; Christopher Baum
Journal:  Mol Ther       Date:  2007-04-03       Impact factor: 11.454

4.  Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity.

Authors:  Ute Modlich; Jens Bohne; Manfred Schmidt; Christof von Kalle; Sabine Knöss; Axel Schambach; Christopher Baum
Journal:  Blood       Date:  2006-07-06       Impact factor: 22.113

5.  Combinatorial incorporation of enhancer-blocking components of the chicken beta-globin 5'HS4 and human T-cell receptor alpha/delta BEAD-1 insulators in self-inactivating retroviral vectors reduces their genotoxic potential.

Authors:  Ali Ramezani; Teresa S Hawley; Robert G Hawley
Journal:  Stem Cells       Date:  2008-09-11       Impact factor: 6.277

6.  Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1.

Authors:  Salima Hacein-Bey-Abina; Alexandrine Garrigue; Gary P Wang; Jean Soulier; Annick Lim; Estelle Morillon; Emmanuelle Clappier; Laure Caccavelli; Eric Delabesse; Kheira Beldjord; Vahid Asnafi; Elizabeth MacIntyre; Liliane Dal Cortivo; Isabelle Radford; Nicole Brousse; François Sigaux; Despina Moshous; Julia Hauer; Arndt Borkhardt; Bernd H Belohradsky; Uwe Wintergerst; Maria C Velez; Lily Leiva; Ricardo Sorensen; Nicolas Wulffraat; Stéphane Blanche; Frederic D Bushman; Alain Fischer; Marina Cavazzana-Calvo
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

7.  The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy.

Authors:  Eugenio Montini; Daniela Cesana; Manfred Schmidt; Francesca Sanvito; Cynthia C Bartholomae; Marco Ranzani; Fabrizio Benedicenti; Lucia Sergi Sergi; Alessandro Ambrosi; Maurilio Ponzoni; Claudio Doglioni; Clelia Di Serio; Christof von Kalle; Luigi Naldini
Journal:  J Clin Invest       Date:  2009-03-23       Impact factor: 14.808

8.  Lentiviral vectors targeting WASp expression to hematopoietic cells, efficiently transduce and correct cells from WAS patients.

Authors:  S Charrier; L Dupré; S Scaramuzza; L Jeanson-Leh; M P Blundell; O Danos; F Cattaneo; A Aiuti; R Eckenberg; A J Thrasher; M Grazia Roncarolo; A Galy
Journal:  Gene Ther       Date:  2006-10-19       Impact factor: 5.250

9.  Retroviral DNA integration: viral and cellular determinants of target-site selection.

Authors:  Mary K Lewinski; Masahiro Yamashita; Michael Emerman; Angela Ciuffi; Heather Marshall; Gregory Crawford; Francis Collins; Paul Shinn; Jeremy Leipzig; Sridhar Hannenhalli; Charles C Berry; Joseph R Ecker; Frederic D Bushman
Journal:  PLoS Pathog       Date:  2006-06-23       Impact factor: 6.823

10.  Insertional gene activation by lentiviral and gammaretroviral vectors.

Authors:  Marieke Bokhoven; Sam L Stephen; Sean Knight; Evelien F Gevers; Iain C Robinson; Yasuhiro Takeuchi; Mary K Collins
Journal:  J Virol       Date:  2008-10-22       Impact factor: 5.103

View more
  166 in total

1.  Gene therapy for canine leukocyte adhesion deficiency with lentiviral vectors using the murine stem cell virus and human phosphoglycerate kinase promoters.

Authors:  Michael J Hunter; Huifen Zhao; Laura M Tuschong; Thomas R Bauer; Tanya H Burkholder; Derek A Persons; Dennis D Hickstein
Journal:  Hum Gene Ther       Date:  2011-04-11       Impact factor: 5.695

2.  Gene therapy for SCID-X1: focus on clinical data.

Authors:  Christopher Baum
Journal:  Mol Ther       Date:  2011-12       Impact factor: 11.454

Review 3.  Hematopoietic stem cell engineering at a crossroads.

Authors:  Isabelle Rivière; Cynthia E Dunbar; Michel Sadelain
Journal:  Blood       Date:  2011-11-17       Impact factor: 22.113

4.  Lentiviral vector integration in the human genome induces alternative splicing and generates aberrant transcripts.

Authors:  Arianna Moiani; Ylenia Paleari; Daniela Sartori; Riccardo Mezzadra; Annarita Miccio; Claudia Cattoglio; Fabienne Cocchiarella; Maria Rosa Lidonnici; Giuliana Ferrari; Fulvio Mavilio
Journal:  J Clin Invest       Date:  2012-04-23       Impact factor: 14.808

Review 5.  Hybrid lentiviral vectors.

Authors:  Waseem Qasim; Conrad A Vink; Adrian J Thrasher
Journal:  Mol Ther       Date:  2010-04-20       Impact factor: 11.454

Review 6.  Hematopoietic-stem-cell-based gene therapy for HIV disease.

Authors:  Hans-Peter Kiem; Keith R Jerome; Steven G Deeks; Joseph M McCune
Journal:  Cell Stem Cell       Date:  2012-02-03       Impact factor: 24.633

7.  Efficiency and safety of O⁶-methylguanine DNA methyltransferase (MGMT(P140K))-mediated in vivo selection in a humanized mouse model.

Authors:  Ruhi Phaltane; Reinhard Haemmerle; Michael Rothe; Ute Modlich; Thomas Moritz
Journal:  Hum Gene Ther       Date:  2014-01-07       Impact factor: 5.695

Review 8.  The transformative potential of HSC gene therapy as a genetic medicine.

Authors:  Pervinder Sagoo; H Bobby Gaspar
Journal:  Gene Ther       Date:  2021-05-26       Impact factor: 5.250

Review 9.  Retroviral vector interactions with hematopoietic cells.

Authors:  Elizabeth M Everson; Grant D Trobridge
Journal:  Curr Opin Virol       Date:  2016-08-10       Impact factor: 7.090

Review 10.  RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA?

Authors:  Sandesh Subramanya; Sang-Soo Kim; N Manjunath; Premlata Shankar
Journal:  Expert Opin Biol Ther       Date:  2010-02       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.